Published in Medical Letter on the CDC and FDA, January 29th, 2006
The research, presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), also showed that Famvir significantly reduced the duration of RGH symptoms including the itching, pain, burning, tingling and tenderness in patients with lesions versus placebo.
Based on these findings, Novartis Pharmaceuticals Corporation filed a supplemental new drug application (sNDA) with the U.S. Food and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA